Afelimomab

An anti-TNF-alpha monoconal antibody which advanced to phase 3 trials for managing sepsis and septic shock, but only offered a marginal improvement over the control arm, and has been abandoned.

Mentioned in

References in periodicals archive

within 24 hours of controls meeting enrollment criteria Sepsis or septic 16 Post-ICU admission shock days 1, 2, or 3 Phase II/III therapeutic trials Severe sepsis 1342 Placebo 12 hours before patients with or controlled receiving drug to without septic day 28 shock (Lenercept trial) Sepsis 48 Placebo 0-168 hours after (Afelimomab trial) controlled drug infusion Sepsis 944 Placebo Baseline to ?

A, B, C's (and D's) for understanding VARs

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.